NovoCure Ltd - Company Profile
Powered by 
All the data and insights you need on NovoCure Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date NovoCure Ltd Strategy Report
- Understand NovoCure Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
NovoCure Ltd (NovoCure) is an oncology company with focus on the development and commercialization of novel delivery systems for the treatment of brain, thoracic and abdomen cancers. Its proprietary Tumor Treating Fields (TTF) technology platform uses electric fields tuned to specific frequencies for disrupting the division of solid tumor cancer cells. The company markets TTF-based delivery systems, Optune Lua for the treatment of malignant pleural mesothelioma; and Optune Gio for the treatment of glioblastoma. The products are indicated in combination with standard chemotherapies. The company has operations in five regions, namely, United States, Germany, Japan, Greater China, and Other international markets. NovoCure is headquartered in Saint Helier, Jersey, the UK.
Headquarters
United Kingdom
Address
No. 4 The Forum, Grenville Street, Saint Helier, Jersey, JE24UF
Website
www.novocure.com
Telephone
44 1534 756700
No of Employees
1,453
Industry
Medical Equipment
Ticker Symbol & Exchange
NVCR (NASD)
Revenue (2023)
$509.3M
-5.3%
(2023 vs 2022)
EPS
XYZ
Net Income (2023)
XYZ
-123.7%
(2023 vs 2022)
Market Cap*
$1.3B
Net Profit Margin (2023)
XYZ
-136.3%
(2023 vs 2022)
* As of and is in US$
NovoCure Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Optune Lua: Malignant Pleural Mesothelioma | - |
| Optune Gio: Glioblastoma | TTFields |
| Pipeline Programs: | Optune Lua |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields Research Program. |
| 2022 | Corporate Changes/Expansions | In November, the company opened a new office in Montreal, Canada. |
| 2022 | Corporate Changes/Expansions | In September, the company announced the creation of its U.S. CNS (central nervous system) Cancers Franchise. |
Competitor Comparison
| Key Parameters | NovoCure Ltd | MDxHealth SA | MagForce AG | Advanz Pharma Corp Ltd | Monteris Medical Inc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | Belgium | Germany | United Kingdom | United States of America |
| City | Saint Helier | Herstal | Berlin | London | Plymouth |
| State/Province | Jersey | - | Baden-Wurttemberg | England | Minnesota |
| No. of Employees | 1,453 | 258 | 69 | 429 | 51 |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| William F. Doyle | Chairman | Executive Board | 2016 | 61 |
| Asaf Danziger | Chief Executive Officer; Director | Executive Board | 2012 | 57 |
| Ashley Cordova | Chief Financial Officer | Senior Management | 2020 | 44 |
| Wilhelmus Groenhuysen | Chief Operating Officer | Senior Management | 2020 | 66 |
| Nicolas Leupin, M.D., Ph.D., MBA | Chief Medical Officer | Senior Management | 2024 | 50 |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward